Faezeh Khorshidian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Faezeh Khorshidian has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ali Bijani
Social Determinant of Health Research Center, Babol University of Medical Sciences, Babol, Iran
4 shared publications Setareh Rassa
Cognitive Neurology, Dementia and Neuropsychiatry Research Center Tehran University of Medical Sciences Tehran Iran
4 shared publications- Angela Hamidia
Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 shared publications - Mahbobeh Faramarzi
Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 shared publications - Farzan Kheirkhah
Department of Psychiatry, School of Medicine, Health Research Institute Babol University of Medical Sciences Babol Iran
2 shared publications - Maryam Noroozian
Cognitive Neurology, Dementia and Neuropsychiatry Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Springer Nature in Discover Mental Health
The diagnostic complexity of psychosis in Parkinson disease
- 15 November 2026
- Published by Springer Nature in Discover Mental Health
Open AccessThe diagnostic complexity of psychosis in Parkinson disease
- Open Access
- 23 October 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (10) , e71868
Conventional MRI Markers and Cognitive Dysfunction in Multiple Sclerosis: An Exploratory Pilot Study
Background: Cognitive impairment is a common and disabling manifestation of multiple sclerosis (MS), yet its structural correlates remain incompletely understood in routine clinical practice. Although advanced neuroimaging has improved our understanding of the underlying mechanisms, its limited accessibility restricts widespread clinical implementation. We aimed to investigate whether conventional MRI markers are associated with domain‐specific cognitive impairment in patients with MS. Methods: In this exploratory cross‐sectional study, 25 adults with clinically confirmed multiple sclerosis underwent cognitive assessment using the standard Persian Montreal Cognitive Assessment (MoCA), version 7.1, and conventional 1.5‐T brain MRI. Conventional MRI measures included lesion burden, lesion topography, and visually rated cortical atrophy. Associations between MRI markers and MoCA‐derived cognitive domains were assessed using Spearman rank correlation with false discovery rate adjustment for multiple testing. Findings: Twenty‐five patients with clinically confirmed MS completed cognitive and MRI assessments. Mean age was 42.4 ± 9.1 years, 56% were women, and the mean MoCA score was 22 ± 7. Periventricular (88%) and juxtacortical/cortical (84%) lesions were the most frequent MRI findings, total T2/FLAIR lesion burden showed only weak correlations with cognitive performance (ρ range −0.02 to 0.29; all FDR‐adjusted p > 0.65). The largest lesion‐based association was observed between infratentorial lesions and concentration ( ρ = −0.48, unadjusted p = 0.018; FDR‐adjusted p = 0.405). Among atrophy measures, GCA showed the strongest association with visuospatial performance ( ρ = 0.51, unadjusted p = 0.012; FDR‐adjusted p = 0.405), with additional moderate trends for concentration ( ρ = 0.40, p = 0.052) and executive function ( ρ = 0.40, p = 0.052). No MRI marker remained statistically significant after correction for multiple comparisons. Interpretation: Although no MRI–cognitive association remained statistically significant after correction for multiple comparisons, several unadjusted associations showed moderate effect sizes and may warrant further investigation. The strongest exploratory associations involved infratentorial lesions and concentration ( ρ = −0.48) and global cortical atrophy and visuospatial performance ( ρ = 0.51). The absence of consistent relationships between overall lesion burden or individual regional MRI markers and cognitive performance suggests that focal structural measures alone may not fully capture the neural substrates of cognitive dysfunction in MS. This pattern provides a rationale for further investigation of distributed, network‐level mechanisms of cognitive dysfunction, while the present findings should be considered hypothesis‐generating rather than confirmatory. Conventional MRI may therefore provide complementary structural information in the clinical assessment of cognitive dysfunction in MS. Larger, adequately powered studies using comprehensive neuropsychological assessment and quantitative, network‐sensitive MRI measures are needed to determine whether these observed patterns are reproducible and clinically meaningful.
- 23 October 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (10) , e71868
Open AccessConventional MRI Markers and Cognitive Dysfunction in Multiple Sclerosis: An Exploratory Pilot Study
Background: Cognitive impairment is a common and disabling manifestation of multiple sclerosis (MS), yet its structural correlates remain incompletely understood in routine clinical practice. Although advanced neuroimaging has improved our understanding of the underlying mechanisms, its limited accessibility restricts widespread clinical implementation. We aimed to investigate whether conventional MRI markers are associated with domain‐specific cognitive impairment in patients with MS. Methods: In this exploratory cross‐sectional study, 25 adults with clinically confirmed multiple sclerosis underwent cognitive assessment using the standard Persian Montreal Cognitive Assessment (MoCA), version 7.1, and conventional 1.5‐T brain MRI. Conventional MRI measures included lesion burden, lesion topography, and visually rated cortical atrophy. Associations between MRI markers and MoCA‐derived cognitive domains were assessed using Spearman rank correlation with false discovery rate adjustment for multiple testing. Findings: Twenty‐five patients with clinically confirmed MS completed cognitive and MRI assessments. Mean age was 42.4 ± 9.1 years, 56% were women, and the mean MoCA score was 22 ± 7. Periventricular (88%) and juxtacortical/cortical (84%) lesions were the most frequent MRI findings, total T2/FLAIR lesion burden showed only weak correlations with cognitive performance (ρ range −0.02 to 0.29; all FDR‐adjusted p > 0.65). The largest lesion‐based association was observed between infratentorial lesions and concentration ( ρ = −0.48, unadjusted p = 0.018; FDR‐adjusted p = 0.405). Among atrophy measures, GCA showed the strongest association with visuospatial performance ( ρ = 0.51, unadjusted p = 0.012; FDR‐adjusted p = 0.405), with additional moderate trends for concentration ( ρ = 0.40, p = 0.052) and executive function ( ρ = 0.40, p = 0.052). No MRI marker remained statistically significant after correction for multiple comparisons. Interpretation: Although no MRI–cognitive association remained statistically significant after correction for multiple comparisons, several unadjusted associations showed moderate effect sizes and may warrant further investigation. The strongest exploratory associations involved infratentorial lesions and concentration ( ρ = −0.48) and global cortical atrophy and visuospatial performance ( ρ = 0.51). The absence of consistent relationships between overall lesion burden or individual regional MRI markers and cognitive performance suggests that focal structural measures alone may not fully capture the neural substrates of cognitive dysfunction in MS. This pattern provides a rationale for further investigation of distributed, network‐level mechanisms of cognitive dysfunction, while the present findings should be considered hypothesis‐generating rather than confirmatory. Conventional MRI may therefore provide complementary structural information in the clinical assessment of cognitive dysfunction in MS. Larger, adequately powered studies using comprehensive neuropsychological assessment and quantitative, network‐sensitive MRI measures are needed to determine whether these observed patterns are reproducible and clinically meaningful.
- Open Access
- 26 September 2026
- Published by Springer Nature in Discover Mental Health
Association between depression, anxiety, and problematic opioid use among adults with cancer at a tertiary referral hospital in northern Iran
- 26 September 2026
- Published by Springer Nature in Discover Mental Health
Open AccessAssociation between depression, anxiety, and problematic opioid use among adults with cancer at a tertiary referral hospital in northern Iran
- Open Access
- 17 August 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (3)
Diagnostic Pitfalls: Uncovering Brain Tumors Misinterpreted as Cognitive and Psychiatric Conditions
Brain tumors, particularly those involving the frontal and temporal lobes, may initially present with psychiatric manifestations such as mood disturbances, personality changes, cognitive impairment, or behavioral abnormalities. These atypical presentations frequently lead to misdiagnosis as primary psychiatric disorders, resulting in delayed diagnosis and treatment. Diagnostic difficulty is further increased by the overlap between psychiatric and neurological symptom profiles, limited access to early neuroimaging or neuropsychiatric assessment, and persistent clinical stigma. We conducted a narrative review of the literature (1990–2025) using PubMed, Embase, PsycINFO and Web of Science, focusing on adult patients initially diagnosed with psychiatric disorders who were later found to have underlying brain tumors. The reviewed evidence indicates that such misdiagnoses are often associated with delayed recognition of neurological disease, missed therapeutic windows, and increased morbidity. Contributing factors include cognitive bias in clinical reasoning, under‐recognition of subtle neurological signs, and systemic limitations in access to diagnostic imaging. Addressing these challenges requires a high index of suspicion in atypical psychiatric presentations, earlier use of neuroimaging, and a multidisciplinary approach integrating neurology, psychiatry, and neurosurgery. Improved clinical awareness, structured assessment pathways, and patient and caregiver education may further reduce diagnostic delays. Overall, early identification of brain tumors presenting with psychiatric symptoms is essential to improve prognosis, prevent irreversible neurological damage, and optimize functional outcomes.
- 17 August 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (3)
Open AccessDiagnostic Pitfalls: Uncovering Brain Tumors Misinterpreted as Cognitive and Psychiatric Conditions
Brain tumors, particularly those involving the frontal and temporal lobes, may initially present with psychiatric manifestations such as mood disturbances, personality changes, cognitive impairment, or behavioral abnormalities. These atypical presentations frequently lead to misdiagnosis as primary psychiatric disorders, resulting in delayed diagnosis and treatment. Diagnostic difficulty is further increased by the overlap between psychiatric and neurological symptom profiles, limited access to early neuroimaging or neuropsychiatric assessment, and persistent clinical stigma. We conducted a narrative review of the literature (1990–2025) using PubMed, Embase, PsycINFO and Web of Science, focusing on adult patients initially diagnosed with psychiatric disorders who were later found to have underlying brain tumors. The reviewed evidence indicates that such misdiagnoses are often associated with delayed recognition of neurological disease, missed therapeutic windows, and increased morbidity. Contributing factors include cognitive bias in clinical reasoning, under‐recognition of subtle neurological signs, and systemic limitations in access to diagnostic imaging. Addressing these challenges requires a high index of suspicion in atypical psychiatric presentations, earlier use of neuroimaging, and a multidisciplinary approach integrating neurology, psychiatry, and neurosurgery. Improved clinical awareness, structured assessment pathways, and patient and caregiver education may further reduce diagnostic delays. Overall, early identification of brain tumors presenting with psychiatric symptoms is essential to improve prognosis, prevent irreversible neurological damage, and optimize functional outcomes.
- Open Access
- 25 June 2026
- Published by Springer Nature in Discover Mental Health
- Vol. 6 (1)
Clinical and literature insights into the frontotemporal dementia and motor neuron disease spectrum
Frontotemporal dementia represents a heterogeneous group of neurodegenerative disorders primarily affecting the frontal and temporal lobes. The overlap between FTD and motor neuron disease is increasingly recognized, presenting a complex clinical syndrome characterized by progressive cognitive, behavioral, and motor decline. We describe a 69-year-old patient with a 4-year history of excessive ambulation. Over the last year, behavioral changes including disorganized conduct, irritability, spitting, and cold water foot immersion developed. The patient experienced compelling auditory hallucinations driving her to walk continuously for up to 10 h per day. Four months prior to admission, gait impairment with frequent falls, along with hyperorality developed. Neurological examination revealed asymmetric mild weakness, marked muscle atrophy of facial and limb muscles, hyperreflexia, and impaired postural control. Brain MRI showed diffuse cerebral atrophy; electrophysiological studies indicated probable motor neuron disease; and TRODAT SPECT demonstrated impaired presynaptic dopaminergic function bilaterally, consistent with parkinsonism. Final diagnosis was frontotemporal dementia with probable motor neuron disease. A review of the literature highlights the clinical, radiological, and molecular features of FTD-MND overlap, emphasizing the role of TDP-43 pathology, C9orf72 mutations, and the need for multidisciplinary management. Current strategies are symptomatic, though novel therapies such as antisense oligonucleotides and biomarkers like neurofilament light chain (NfL) show promise. This case highlights the diagnostic complexity of FTD with MND overlap syndrome, emphasizing the need for comprehensive clinical, neuroimaging, and electrophysiological evaluation. Multimodal treatment approaches focusing on behavioral symptoms and functional support are essential for optimizing patient outcomes.
- 25 June 2026
- Published by Springer Nature in Discover Mental Health
- Vol. 6 (1)
Open AccessClinical and literature insights into the frontotemporal dementia and motor neuron disease spectrum
Frontotemporal dementia represents a heterogeneous group of neurodegenerative disorders primarily affecting the frontal and temporal lobes. The overlap between FTD and motor neuron disease is increasingly recognized, presenting a complex clinical syndrome characterized by progressive cognitive, behavioral, and motor decline. We describe a 69-year-old patient with a 4-year history of excessive ambulation. Over the last year, behavioral changes including disorganized conduct, irritability, spitting, and cold water foot immersion developed. The patient experienced compelling auditory hallucinations driving her to walk continuously for up to 10 h per day. Four months prior to admission, gait impairment with frequent falls, along with hyperorality developed. Neurological examination revealed asymmetric mild weakness, marked muscle atrophy of facial and limb muscles, hyperreflexia, and impaired postural control. Brain MRI showed diffuse cerebral atrophy; electrophysiological studies indicated probable motor neuron disease; and TRODAT SPECT demonstrated impaired presynaptic dopaminergic function bilaterally, consistent with parkinsonism. Final diagnosis was frontotemporal dementia with probable motor neuron disease. A review of the literature highlights the clinical, radiological, and molecular features of FTD-MND overlap, emphasizing the role of TDP-43 pathology, C9orf72 mutations, and the need for multidisciplinary management. Current strategies are symptomatic, though novel therapies such as antisense oligonucleotides and biomarkers like neurofilament light chain (NfL) show promise. This case highlights the diagnostic complexity of FTD with MND overlap syndrome, emphasizing the need for comprehensive clinical, neuroimaging, and electrophysiological evaluation. Multimodal treatment approaches focusing on behavioral symptoms and functional support are essential for optimizing patient outcomes.
- Open Access
- 5 May 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (2) , e70010
Emotional Intelligence and Its Influence on Internet Addiction and Eating Disorders: A Quantitative Approach
Emotional intelligence (EI) has emerged as a critical determinant of psychological well‐being, influencing individuals' capacity to manage stress, navigate social challenges, and regulate emotions. However, its role in shaping vulnerability to behavioral disorders—particularly eating disorders (ED) and Internet addiction (IA)—remains complex and underexplored. This study investigates the dual role of emotional intelligence as both a protective factor and a potential risk amplifier for eating disorder and compulsive Internet use among medical students. In this cross‐sectional study, 400 clinical‐stage medical students from the University of Medical Sciences in Northern Iran completed validated assessments of EI (Bradberry & Greaves), eating attitudes (EAT‐26), and Internet addiction (IAT). Correlation and multiple regression analyses were conducted to evaluate the predictive value of EI subcomponents—well‐being, self‐control, emotionality, and sociability—on ED and IA symptoms. Higher total EI scores were significantly associated with lower ED symptoms (r = −0.45, p < 0.001). Regression analysis identified well‐being and self‐control as the strongest negative predictors of ED (R 2 = 0.36). Unexpectedly, EI was positively correlated with IA (r = 0.32, p < 0.001), with emotionality, well‐being, and self‐control positively predicting IA severity (R 2 = 0.24). Sociability did not significantly predict either outcome. These findings challenge the traditional view of EI as universally adaptive. While EI appears protective against disordered eating by enhancing emotional resilience and self‐regulation, it may concurrently increase vulnerability to Internet overuse, potentially by facilitating online emotional engagement or avoidance behaviors. This paradox highlights the importance of dimension‐specific, nuanced interventions in mental health and behavioral risk prevention among young adults.
- 5 May 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (2) , e70010
Open AccessEmotional Intelligence and Its Influence on Internet Addiction and Eating Disorders: A Quantitative Approach
Emotional intelligence (EI) has emerged as a critical determinant of psychological well‐being, influencing individuals' capacity to manage stress, navigate social challenges, and regulate emotions. However, its role in shaping vulnerability to behavioral disorders—particularly eating disorders (ED) and Internet addiction (IA)—remains complex and underexplored. This study investigates the dual role of emotional intelligence as both a protective factor and a potential risk amplifier for eating disorder and compulsive Internet use among medical students. In this cross‐sectional study, 400 clinical‐stage medical students from the University of Medical Sciences in Northern Iran completed validated assessments of EI (Bradberry & Greaves), eating attitudes (EAT‐26), and Internet addiction (IAT). Correlation and multiple regression analyses were conducted to evaluate the predictive value of EI subcomponents—well‐being, self‐control, emotionality, and sociability—on ED and IA symptoms. Higher total EI scores were significantly associated with lower ED symptoms (r = −0.45, p < 0.001). Regression analysis identified well‐being and self‐control as the strongest negative predictors of ED (R 2 = 0.36). Unexpectedly, EI was positively correlated with IA (r = 0.32, p < 0.001), with emotionality, well‐being, and self‐control positively predicting IA severity (R 2 = 0.24). Sociability did not significantly predict either outcome. These findings challenge the traditional view of EI as universally adaptive. While EI appears protective against disordered eating by enhancing emotional resilience and self‐regulation, it may concurrently increase vulnerability to Internet overuse, potentially by facilitating online emotional engagement or avoidance behaviors. This paradox highlights the importance of dimension‐specific, nuanced interventions in mental health and behavioral risk prevention among young adults.
- Open Access
- 30 April 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (2)
Breaking the Seizure Code: Challenges in Identifying and Managing Functional and Dissociative Seizures
Functional and dissociative seizures (FDS), formerly known as psychogenic non‐epileptic seizures (PNES), closely mimic epileptic seizures but are not caused by abnormal epileptiform activity in the cerebral cortex. This resemblance poses significant challenges for accurate diagnosis and effective management. Misdiagnosis is common and often results in delayed appropriate treatment, thereby increasing the overall burden on patients. This review spotlights cutting‐edge strategies to distinguish FDS from epilepsy, emphasizing innovative diagnostics and holistic therapies to transform patient outcomes. A narrative review was conducted using systematic searches of PubMed, Scopus, and PsycINFO (2000–2025). Data on clinical features, diagnostics, comorbidities, and therapies were thematically synthesized to highlight challenges and guide clinical practice. FDS intricately blend neurological symptoms with psychological origins, making diagnosis challenging. Video‐EEG combined with psychiatric evaluation is essential. Treatment shifts focus from medication to psychological therapies, requiring multidisciplinary care. Education is a vital therapeutic tool in FDS management. By helping patients and families understand that FDS are real, treatable conditions—not fabricated—stigma is reduced, fostering acceptance. Establishing a strong therapeutic alliance based on empathy, transparency, and shared decision‐making turns treatment into a collaborative, motivating process, improving adherence and outcomes. FDS are complex, straddling neurology and psychiatry, with diagnostic and treatment challenges. Accurate diagnosis using video‐EEG and psychiatric evaluation is crucial to avoid mismanagement. Effective care demands multidisciplinary psychological treatments, patient education, and strong therapeutic alliances. Future research should enhance diagnostics and therapies through clinical trials and biomarker studies.
- 30 April 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (2)
Open AccessBreaking the Seizure Code: Challenges in Identifying and Managing Functional and Dissociative Seizures
Functional and dissociative seizures (FDS), formerly known as psychogenic non‐epileptic seizures (PNES), closely mimic epileptic seizures but are not caused by abnormal epileptiform activity in the cerebral cortex. This resemblance poses significant challenges for accurate diagnosis and effective management. Misdiagnosis is common and often results in delayed appropriate treatment, thereby increasing the overall burden on patients. This review spotlights cutting‐edge strategies to distinguish FDS from epilepsy, emphasizing innovative diagnostics and holistic therapies to transform patient outcomes. A narrative review was conducted using systematic searches of PubMed, Scopus, and PsycINFO (2000–2025). Data on clinical features, diagnostics, comorbidities, and therapies were thematically synthesized to highlight challenges and guide clinical practice. FDS intricately blend neurological symptoms with psychological origins, making diagnosis challenging. Video‐EEG combined with psychiatric evaluation is essential. Treatment shifts focus from medication to psychological therapies, requiring multidisciplinary care. Education is a vital therapeutic tool in FDS management. By helping patients and families understand that FDS are real, treatable conditions—not fabricated—stigma is reduced, fostering acceptance. Establishing a strong therapeutic alliance based on empathy, transparency, and shared decision‐making turns treatment into a collaborative, motivating process, improving adherence and outcomes. FDS are complex, straddling neurology and psychiatry, with diagnostic and treatment challenges. Accurate diagnosis using video‐EEG and psychiatric evaluation is crucial to avoid mismanagement. Effective care demands multidisciplinary psychological treatments, patient education, and strong therapeutic alliances. Future research should enhance diagnostics and therapies through clinical trials and biomarker studies.
- Open Access
- 30 April 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (2)
MELAS‐Like Mitochondrial Encephalopathy With Catatonia Associated With a Pathogenic MT‐ND3 (m.10158 T > C) Mutation: A Case Report and Literature Review
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke‐like episodes (MELAS) is a rare multisystem mitochondrial disorder primarily caused by mutations in mitochondrial DNA. While it typically presents with stroke‐like episodes, seizures, and lactic acidosis, recent evidence highlights a broader clinical spectrum, including neuropsychiatric manifestations such as psychosis. Although mutations in the MT‐ND3 gene are primarily associated with Leigh syndrome, they have also been linked to MELAS‐like presentations, underscoring the diagnostic complexity and the need for thorough genetic evaluation. We report the case of an 18‐year‐old Afghan female with a complex clinical history, including early‐onset seizures, Wilms tumor treated with chemotherapy, progressive peripheral neuropathy, and recent‐onset catatonia. Initial assessments suggested Charcot–Marie–Tooth disease; however, Whole mitochondrial genome sequencing identified a homoplasmic mitochondrial DNA variant in the MT‐ND3 gene, designated according to standard mitochondrial nomenclature as m.10158 T > C (MT‐ND3), which results in a missense amino acid substitution (p. Ser34Pro). Variant interpretation was conducted in accordance with ACMG/AMP guidelines adapted for mitochondrial DNA and was cross‐referenced with MITOMAP and ClinGen mitochondrial expert panel classifications. Laboratory findings indicated lactic acidosis, elevated ammonia, and increased CPK levels. The patient responded rapidly to lorazepam for catatonia and showed functional recovery following the initiation of a mitochondrial cocktail and integrated neurorehabilitation. Although MELAS is most commonly linked to the m.3243 A > G mutation in MT‐TL1, emerging reports associate MT‐ND3 variants with a broader phenotypic spectrum, including neuropathy and psychiatric symptoms. Neuropsychiatric features are increasingly recognized in mitochondrial disorders and may precede classical neurological signs. Genetic testing and metabolic profiling are essential for accurate diagnosis, particularly in atypical cases or resource‐limited settings. Treatment remains largely supportive, with variable responses to mitochondrial cocktails and symptomatic management. This case expands the phenotypic spectrum of MT‐ND3–related mitochondrial encephalopathy with MELAS‐like features, including catatonia and peripheral neuropathy, and highlights the clinical variability associated with pathogenic complex I–related mitochondrial DNA mutations. A multidisciplinary approach—including psychiatry, neurology, genetics, and rehabilitation—is crucial for managing these complex presentations.
- 30 April 2026
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 30 (2)
Open AccessMELAS‐Like Mitochondrial Encephalopathy With Catatonia Associated With a Pathogenic MT‐ND3 (m.10158 T > C) Mutation: A Case Report and Literature Review
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke‐like episodes (MELAS) is a rare multisystem mitochondrial disorder primarily caused by mutations in mitochondrial DNA. While it typically presents with stroke‐like episodes, seizures, and lactic acidosis, recent evidence highlights a broader clinical spectrum, including neuropsychiatric manifestations such as psychosis. Although mutations in the MT‐ND3 gene are primarily associated with Leigh syndrome, they have also been linked to MELAS‐like presentations, underscoring the diagnostic complexity and the need for thorough genetic evaluation. We report the case of an 18‐year‐old Afghan female with a complex clinical history, including early‐onset seizures, Wilms tumor treated with chemotherapy, progressive peripheral neuropathy, and recent‐onset catatonia. Initial assessments suggested Charcot–Marie–Tooth disease; however, Whole mitochondrial genome sequencing identified a homoplasmic mitochondrial DNA variant in the MT‐ND3 gene, designated according to standard mitochondrial nomenclature as m.10158 T > C (MT‐ND3), which results in a missense amino acid substitution (p. Ser34Pro). Variant interpretation was conducted in accordance with ACMG/AMP guidelines adapted for mitochondrial DNA and was cross‐referenced with MITOMAP and ClinGen mitochondrial expert panel classifications. Laboratory findings indicated lactic acidosis, elevated ammonia, and increased CPK levels. The patient responded rapidly to lorazepam for catatonia and showed functional recovery following the initiation of a mitochondrial cocktail and integrated neurorehabilitation. Although MELAS is most commonly linked to the m.3243 A > G mutation in MT‐TL1, emerging reports associate MT‐ND3 variants with a broader phenotypic spectrum, including neuropathy and psychiatric symptoms. Neuropsychiatric features are increasingly recognized in mitochondrial disorders and may precede classical neurological signs. Genetic testing and metabolic profiling are essential for accurate diagnosis, particularly in atypical cases or resource‐limited settings. Treatment remains largely supportive, with variable responses to mitochondrial cocktails and symptomatic management. This case expands the phenotypic spectrum of MT‐ND3–related mitochondrial encephalopathy with MELAS‐like features, including catatonia and peripheral neuropathy, and highlights the clinical variability associated with pathogenic complex I–related mitochondrial DNA mutations. A multidisciplinary approach—including psychiatry, neurology, genetics, and rehabilitation—is crucial for managing these complex presentations.
- Open Access
- 1 March 2026
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 19 (01) , 001-009
REM Sleep Behavior Disorder as a Key Predictor of Cognitive Decline: Insights from a Narrative Review
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia. Mounting evidence positions RBD as a critical prodromal indicator of synucleinopathies—particularly Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)—with a significant link to progressive cognitive decline. To explore the underlying pathophysiological mechanisms connecting RBD with cognitive impairment, to delineate the neuropsychological profile of the affected individuals, and to critically evaluate the current diagnostic tools and therapeutic challenges. We synthesized data from clinical cohort studies, structural and functional neuroimaging modalities (magnetic resonance imaging [MRI], fluorodeoxyglucose positron-emission tomography [FDG-PET], and single-photon emission computed tomography [SPECT]), molecular biomarkers—including alpha-synuclein seeding assays—and genetic studies focusing on mutations such as glucocerebrosidase, β, acid (GBA) and synuclein alpha (SNCA). Individuals with idiopathic RBD (iRBD) frequently exhibit early deficits in executive function, attention, visuospatial abilities, and episodic memory—often years before motor symptoms manifest. Pathologically, the spread of alpha-synuclein aggregates from REM sleep-regulating nuclei in the brainstem to limbic and neocortical areas mirrors the trajectory of cognitive decline. Cholinergic-system degeneration, particularly in the pedunculopontine nucleus and basal forebrain, further contributes to the neurocognitive symptoms. Neuroimaging consistently reveals frontal and temporal cortical thinning, along with posterior hypometabolism characteristic of synucleinopathies. Biomarker analysis shows altered cerebrospinal fluid (CSF) amyloid-beta and -tau levels, as well as positive alpha-synuclein real-time quaking-induced conversion (RT-QuIC) assay results. Genetic predispositions strongly influence the risk and rate of progression. A powerful early biomarker for cognitive decline associated with synucleinopathies, the early identification of RDB through comprehensive neuropsychological profiling, advanced imaging techniques, and molecular diagnostic methods is essential for risk stratification and monitoring. Although disease-modifying therapies remain elusive, a deeper understanding of shared pathogenic pathways offers promising avenues for targeted neuroprotective strategies.
- 1 March 2026
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 19 (01) , 001-009
Open AccessREM Sleep Behavior Disorder as a Key Predictor of Cognitive Decline: Insights from a Narrative Review
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia. Mounting evidence positions RBD as a critical prodromal indicator of synucleinopathies—particularly Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)—with a significant link to progressive cognitive decline. To explore the underlying pathophysiological mechanisms connecting RBD with cognitive impairment, to delineate the neuropsychological profile of the affected individuals, and to critically evaluate the current diagnostic tools and therapeutic challenges. We synthesized data from clinical cohort studies, structural and functional neuroimaging modalities (magnetic resonance imaging [MRI], fluorodeoxyglucose positron-emission tomography [FDG-PET], and single-photon emission computed tomography [SPECT]), molecular biomarkers—including alpha-synuclein seeding assays—and genetic studies focusing on mutations such as glucocerebrosidase, β, acid (GBA) and synuclein alpha (SNCA). Individuals with idiopathic RBD (iRBD) frequently exhibit early deficits in executive function, attention, visuospatial abilities, and episodic memory—often years before motor symptoms manifest. Pathologically, the spread of alpha-synuclein aggregates from REM sleep-regulating nuclei in the brainstem to limbic and neocortical areas mirrors the trajectory of cognitive decline. Cholinergic-system degeneration, particularly in the pedunculopontine nucleus and basal forebrain, further contributes to the neurocognitive symptoms. Neuroimaging consistently reveals frontal and temporal cortical thinning, along with posterior hypometabolism characteristic of synucleinopathies. Biomarker analysis shows altered cerebrospinal fluid (CSF) amyloid-beta and -tau levels, as well as positive alpha-synuclein real-time quaking-induced conversion (RT-QuIC) assay results. Genetic predispositions strongly influence the risk and rate of progression. A powerful early biomarker for cognitive decline associated with synucleinopathies, the early identification of RDB through comprehensive neuropsychological profiling, advanced imaging techniques, and molecular diagnostic methods is essential for risk stratification and monitoring. Although disease-modifying therapies remain elusive, a deeper understanding of shared pathogenic pathways offers promising avenues for targeted neuroprotective strategies.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Alopecia Areata and Its Association With Anxiety and Depression: A Case–Control Study in Patients Referred to Dermatology Clinics
Background: Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss that may present as localized or widespread involvement. Beyond its physical manifestations, AA is associated with considerable psychological distress, particularly anxiety and depression. This study aimed to evaluate the association between anxiety and depression in individuals with AA compared to healthy controls. Methods: In this case–control study, 70 patients were diagnosed with AA and 70 healthy controls completed the Hospital Anxiety and Depression Scale (HADS). Descriptive statistics were reported as mean ± standard deviation for quantitative variables and frequency (percentage) for qualitative variables. Independent t ‐tests, ANOVA, Pearson’s correlation coefficient, and multivariate linear regression analyses were applied to examine the association between psychological outcomes and clinical variables, including disease duration, severity, stage, treatment modality, and affected area. A p value < 0.05 was considered statistically significant. Results: Patients with AA showed significantly higher levels of anxiety and depression compared to healthy controls ( p < 0.001). Anxiety scores were higher in patients with a disease duration longer than six months ( p = 0.014). However, anxiety levels were not significantly associated with disease severity, stage, treatment modality, or affected area. In contrast, depression scores were higher in patients with severe AA ( p = 0.007), while no significant differences were observed with respect to disease duration, stage, treatment modality, or affected area. Conclusion: Patients with AA experience higher levels of anxiety and depression compared to healthy individuals. Longer disease duration is associated with increased anxiety, while greater disease severity is a significant predictor of depression. These findings highlight the need for routine psychological screening in patients with AA in dermatology practice; however, longitudinal studies are required to establish causality and clarify long‐term implications.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessAlopecia Areata and Its Association With Anxiety and Depression: A Case–Control Study in Patients Referred to Dermatology Clinics
Background: Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss that may present as localized or widespread involvement. Beyond its physical manifestations, AA is associated with considerable psychological distress, particularly anxiety and depression. This study aimed to evaluate the association between anxiety and depression in individuals with AA compared to healthy controls. Methods: In this case–control study, 70 patients were diagnosed with AA and 70 healthy controls completed the Hospital Anxiety and Depression Scale (HADS). Descriptive statistics were reported as mean ± standard deviation for quantitative variables and frequency (percentage) for qualitative variables. Independent t ‐tests, ANOVA, Pearson’s correlation coefficient, and multivariate linear regression analyses were applied to examine the association between psychological outcomes and clinical variables, including disease duration, severity, stage, treatment modality, and affected area. A p value < 0.05 was considered statistically significant. Results: Patients with AA showed significantly higher levels of anxiety and depression compared to healthy controls ( p < 0.001). Anxiety scores were higher in patients with a disease duration longer than six months ( p = 0.014). However, anxiety levels were not significantly associated with disease severity, stage, treatment modality, or affected area. In contrast, depression scores were higher in patients with severe AA ( p = 0.007), while no significant differences were observed with respect to disease duration, stage, treatment modality, or affected area. Conclusion: Patients with AA experience higher levels of anxiety and depression compared to healthy individuals. Longer disease duration is associated with increased anxiety, while greater disease severity is a significant predictor of depression. These findings highlight the need for routine psychological screening in patients with AA in dermatology practice; however, longitudinal studies are required to establish causality and clarify long‐term implications.